



RAPID NUTRITION PLC

CORPORATE GOVERNANCE

CONTENTS

ACCOUNTING PRINCIPLES

BUSINESS OF THE GROUP

- Company Information
- Board of Directors and Management
- Shareholders and Related Party Transactions
- Description of the share capital and the shares

TAXATION

GLOSSARY OF TERMS

Accounting Principles

The financial information of the Company contained in this document is prepared in accordance with the International Financial Reporting Standards (**IFRS**) as adopted by the European Union and with those parts of the Companies Act 2006 of the United Kingdom applicable to companies reporting under IFRS.

1. BUSINESS OF THE GROUP

1.1. Overview

Rapid Nutrition PLC (“the Company”) was incorporated to act as a holding company for the group of companies, Rapid Nutrition Canada Inc. and its subsidiaries, Rapid Nutrition Pty Ltd and The Plant-Based Bundle Pty Ltd. The purpose of Rapid Nutrition Canada Inc. was to obtain CDS Eligibility for its Common Shares. CDS Clearing offers the New York Link and DTC Direct Link services to transact Canada-U.S. cross-border settlements and to provide custody services for U.S.-based securities via DTC. Shares that are CDS eligible often increase trading volume. In addition, CDS eligibility addresses the issue that many US firms have that prohibit trading in shares that are not either CDS or DTC eligible. As Rapid Nutrition moves forward with its business plans, CDS eligibility will extend its reach to a broader audience of investors, both in North America and internationally and further support its shareholders.

COMPANY INFORMATION

1.2. General Information

1.2.1 Name, Registered Office, Location

The name of the Company is Rapid Nutrition PLC. The Company's the registered address is Suite A, 82 James Carter Road, Mildenhall Suffolk IP28 7DE124, United Kingdom and the Company's head office is located at 747 Lytton Road, Murarrie QLD 4172, Australia.

The whole business of the Company is operated through its subsidiary Rapid Nutrition Pty Ltd, 747 Lytton Road, Murarrie QLD 4172, Australia.

1.2.2 Incorporation, Duration

The Company was incorporated in England and Wales on 11 January 2012 under the name Rapid Nutrition PLC. The Company exists since its incorporation and its duration is not limited.

1.2.3 System of Law, Legal Form

The Company is a public limited company (PLC) incorporated under the laws of England and Wales and operating pursuant to the UK Companies Act 1985 (as amended) and the Companies Act 2006 (Act).

1.2.4 Purpose

The laws of England and Wales require companies to specify their nature of business according to the standard industrial classification of economic activities (UK SIC Code) when filing with Companies House, which is the United Kingdom's registrar of companies.

The Company business purpose and activities are included under the UK SIC Code 21100 "Manufacture of basic pharmaceutical products" which includes provitamins, vitamins and their derivatives (manufacture) as well as mineral and pharmaceutical nutritional ingredients for food and feeding stuff (manufacture).

1.2.5 Register

The Company is registered through Companies House, United Kingdom since its incorporation under the company number 7905640.

1.2.6 Group Structure

Rapid Nutrition PLC ("the Company") was incorporated to act as a holding company for the group of companies, Rapid Nutrition Canada Inc. and its subsidiaries, Rapid Nutrition Pty Ltd and The Plant-Based Bundle Pty Ltd. The purpose of Rapid Nutrition Canada Inc. was to obtain CDS Eligibility for its Common Shares. CDS Clearing offers the New York Link and DTC Direct Link services to transact Canada-U.S. cross-border settlements and to provide custody services for U.S.-based securities via DTC. Shares that are CDS eligible often increase trading volume. In addition, CDS eligibility addresses the issue that many US firms have that prohibit trading in shares that are not either CDS or DTC eligible. As Rapid Nutrition moves forward with its business plans, CDS eligibility will extend its reach to a broader audience of investors, both in North America and internationally and further support its shareholders.

Other companies include in the group, The Plant-Based Bundle Pty Ltd, incorporated on the 18th of February 2018. Additionally, a 48% shareholding in Rapid Nutrition Science Pty Ltd which was incorporated on the 28 April 2020 to hold any new intellectual property.

BOARD OF DIRECTORS AND MANAGEMENT

1.3. In General

The Company is a public limited company (PLC) incorporated under the laws of England and Wales.

The corporate bodies of a PLC under the laws of England and Wales consist of a Board of Directors and any committees to which the Board of Directors choose to delegate their powers.

The respective rights and responsibilities of these bodies are set forth in the Companies Act 2006, the Company's Articles of Association and any terms of reference of the committees.

The board of directors of a PLC is responsible for the management of the company's business. Each director, and the board of directors as a whole, owes duties to the company. These duties are: To act within their powers; to promote the success of the company; to exercise independent judgment; to exercise reasonable care, skill and diligence; to avoid conflicts of interest; not to accept benefits from third parties; and to declare interests in any proposed transactions or arrangements with the Company.

English company law does not distinguish between a management board and a supervisory board. The directors can either be executive or non-executive members but all owe the same statutory duties to the company.

1.4. Board of Directors

1.4.1 General

According to Articles 82 and 83 of the Company's Articles, Directors are appointed by ordinary resolution of the shareholders or by a decision of the directors. As a matter of best practice, the directors of the Company rotate for re-election at each Annual General Meeting of the Company, although this is not required under the Company's articles of association. The Company is required to have a minimum of two directors. There is no distinction drawn between executive and non-executive directors under the laws of England and Wales. Any person occupying the position of director, by whatever name called, will be considered to be a director.

Currently, the Company's Board of Directors consists of three members.

1.4.2 Members of the Board of Directors

Simon St Ledger, executive Director and CEO (Nationality: Australian)

Appointed to office: 11 January 2012

Simon St Ledger has been a personal trainer and dietary consultant, and an advisor to numerous health clubs and organisations. In the two decades that he has been in the industry, Simon St Ledger has amongst other things managed national fitness equipment suppliers and was named a finalist for the 2012 Brisbane Young Entrepreneur Award. Simon St Ledger also made the Subsidiary worthy of the 2013 Premier of Queensland's Export Award in the Health and Biotechnology category. This recognition earned the Subsidiary a place in the national finals of the 51st Australian Government Export Awards, representing Queensland in the small business category.

Shayne Kellow, non-executive Director (Nationality: Australian)

Appointed to office: 13 October 2017

Shayne Kellow has over twenty-five years of experience in institutional and business development, corporate finance and international sales. He has experience, establishing

global distribution networks within the healthcare industry, in particular in South-East Asia, Middle East and the Americas. Previous roles of Shayne Kellow include Business Operations Manager of the Australian Business Development Centre which involved mentoring and advising Business Startup for over 250 new businesses. Further, he was the Founding Director of Elmore Oil, a successful healthcare company manufacturing and distributing natural lotions with therapeutic benefits to over 12 countries.

Jeffrey Reingold, non-executive Director (Nationality: Australian)

Appointed to office: 9 November 2022

Jeffrey Reingold boasts extensive experience in media and marketing for international businesses and organisations. He excels at reaching broad audiences, promoting brands and filming with a focus on health and wellness. Reingold launched his career in North America, a key market for Rapid Nutrition, working for Metro-Goldwyn-Mayer/United Artists. Jeff's outstanding experience in working with corporations of all sizes and using marketing to expand reach and networking make him the perfect addition to the board.

1.4.3 Committees

As envisaged by the UK Corporate Governance Code, which is not statutory law but a set of principles that represent good corporate governance practice and has been widely adopted by UK companies, the Board has established Audit, Remuneration, Nomination Committees.

Audit Committee: The Audit Committee has responsibility for, among other things, the monitoring of the financial integrity of the financial statements of the Group and the involvement of the Group's auditors in that process. It focuses in particular on compliance with accounting policies and ensuring that an effective system of internal financial controls is maintained. The ultimate responsibility for reviewing and approving the annual report and accounts and the half-yearly reports remains with the Board. The Audit Committee will normally meet at least three times a year at the appropriate times in the reporting and audit cycle.

The terms of reference of the Audit Committee cover such issues as membership and the frequency of meetings, together with requirements for quorum and notice procedure and the right to attend meetings. The responsibilities of the Audit Committee covered in the terms of reference are: external audit, internal audit, financial reporting and internal controls and risk management. The terms of reference also set out the authority of the committee to carry out its responsibilities. The Audit Committee's terms of reference require that it comprise two or more independent non-executive Directors, and at least one person who is to have significant, recent and relevant financial experience.

The Audit Committee currently comprises two members being independent non-executive Director, and independent non-executive adviser. The committee is chaired by the non-executive director.

The ultimate responsibility for reviewing and approving the annual report and accounts and the half-yearly reports will remain with the Board.

Remuneration Committee: The Remuneration and Nomination Committee has responsibility for considering and making recommendations to the Board in respect of appointments to the Board, the Board committees and the chairmanship of the Board committees. It is also responsible for keeping the structure, size and composition of the Board

under regular review, and for making recommendations to the Board with regard to any changes necessary.

The responsibilities of the Remuneration and Nomination Committee covered in its terms of reference include: review of the Board composition; appointing new Directors; reappointment and re-election of existing Directors; succession planning, taking into account the skills and expertise that will be needed on the Board in the future; reviewing time required from non-executive directors; determining membership of other Board committees; and ensuring external facilitation of the evaluation of the Board.

The Committee is further responsible for the determination of the terms and conditions of employment, remuneration and benefits of each of the Chairman, executive Directors, members of the executive and the company secretary, including pension rights and any compensation payments, and recommending and monitoring the level and structure of remuneration for senior management and the implementation of share option or other performance-related schemes. The Remuneration and Nomination Committee will meet at least twice a year.

The terms of reference of the Remuneration and Nomination Committee also cover such issues as membership and frequency of meetings, together with the requirements for quorum and no-tice procedure and the right to attend meetings. The responsibilities of the Remuneration and Nomination Committee covered in its terms of reference are: determining and monitoring policy on and setting levels of remuneration; early termination, performance-related pay and pension arrangements; reporting and disclosure of remuneration policy; share schemes (including the annual level of awards); obtaining information on remuneration in other companies; and selecting, appointing and terminating remuneration consultants. The terms of reference also set out the reporting responsibilities and the authority of the committee to carry out its responsibilities.

The Remuneration and Nomination Committee comprises 2 members; non-executive director and an independent non-executive adviser. The committee is chaired by non-executive adviser.

1.4.4 Appointed Executive Officers

English law does not distinguish between a management board and a board of directors with a supervisory function. The directors are responsible for the management of the company's business. There are executive and non-executive directors. Directors may delegate certain powers and tasks to third parties.

1.4.5 Company Secretary

Public companies governed by the Companies Act are required to appoint a Company Secretary according to section 271 of the Companies Act 2006.

The Company Secretary of the Company is Elemental Company Secretary Limited with its business address at 27 Old Gloucester Street, London WC1N 3AX, United Kingdom. The Company Secretary's general responsibilities are:

- annual compliance services;
- support for the general meeting of the Company;
- drafting of the notice of general meeting;
- drafting of the proxy form, board minutes calling the meeting, chairman's script and ancillary documents;

- ad hoc advice on the proposed resolutions;
- attendance at the meeting in person or by telephone conference;
- drafting of the minutes of the meeting; and
- filing any relevant resolutions with Companies House.

1.4.6 Positions held by the Members of the Board of Directors in the last five Years

The members of the Board of Directors of the Company have not been, during the last five years or currently are, members of the administrative, management or supervisory bodies under company law, or partners, of any other listed and major companies.

1.4.7 Business Address

The business address of all three members of the Board of Directors and the Chief Financial Officer is 747 Lytton Road, Murarrie QLD 4172, Australia.

1.5. Compensation, Ownership of Shares and Option Rights in the Company

The following table shows the number of Shares and option rights in the Company held directly or indirectly by individual members of the Board of Directors and the Chief Financial Officer of the Company. The applicable percentage ownership is based on 4,785,474 Shares outstanding as at 11 January, 2024

	No. of Shares	Voting Rights (%)
Simon St Ledger	2,448	0.05%
Jeffrey Reingold	0	-
Shayne Kellow	272	0.005%
Michael Zhu (Chief Financial Officer)	0	-
Total	2,720	0.055%

Compensation:

The Remuneration committee review the Executive and Non-Executive Director salaries and fees each year. Adjustments are made to reflect the comparative fees paid to a band of similar sized listed companies.

The Group operates on a strictly ‘capital efficient’ approach and therefore directors remuneration has been based on conservative market matching rates each year in order to act in the best interest of the Company during the Company’s growth phase.

Simon St Ledger’s employment terms, as formalized by board resolution and contract, dated 1st July 2019 which specifies a salary of AUD\$165, 000 per annum. A car allowance up to AUD\$1000 per month and the required Super/pension payments at 9.5% per annum. The director will also be entitled to an executive bonus which shall not exceed 10% of remuneration and determined at the sole discretion of the board.

Shayne Kellow has been provided with the use of a vehicle owned by the consolidated entity for their personal use. Mr Kellow’s vehicle was acquired in a prior period for AUD\$50,459

Jeffrey Reingold’s was provided with relevant contract that has been executed prior to the appointment. The fee payable for carrying out her duties is a fee of \$1000 per General Meeting and \$200 per board meeting.

1.6. Employee Participation Program

The Company has no employee participation programs in place.

1.7. Statutory and Group Auditor

The existing auditing mandate was assumed by HGA Accountants & Financial Consultants Limited 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD United Kingdom.

SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

1.8. Major Shareholders

Since its Listing at Euronext Growth Paris on 22 June 2021, the Company has adopt Euronext Growth Market Rules 4.3.1 Disclosure of certain events for Issuers of equity securities and equivalent securities.

Rule 4.3.1 of the Euronext Growth Market Rule Book reads as follows:

Without prejudice to National Regulations, each Issuer of Equity Securities and equivalent Securities (including closed-end funds) shall make public within five (5) Trading Days of becoming aware, any situation where a person, acting alone or in concert, reaches, exceeds or falls below a major holding threshold of fifty percent (50%) or ninety percent (90%) of the capital or voting rights.

As of 11 January 2024, the shareholder base notified to the Company and disclosed consists of the following persons and entities (percentage figures refer to a percentage of voting rights in relation to the voting rights of the Shares published).

Major Shareholders	No. of Shares/ No. of voting rights	Proportion of voting rights
Atlas Special Opportunities II, LLC	458,920,859	9.59%

The information above is voluntarily provided from the website as of 11 January 2024 and is based on disclosures the Company voluntarily received from third parties. The information presented in the table above is to the best of the Company's knowledge accurate and up to date and subject to change (on short notice).

1.9. Public Purchase Offers

Laws of England and Wales: The Company has been advised that the provisions of the City Code on Takeovers and Mergers (UK Takeover Code) do not apply to the Company as at the date of this document since the directors do not consider that the Company has its place of central management and control in the United Kingdom, the Channel Islands or the Isle of Man. In the event that this changed in the future, the UK Takeover Code would apply to the Company.

Articles of Association: The Articles of Association of the Company do not contain any provisions regarding offer obligations. The Company's 'Articles of Association' can be viewed here: *Search Path: rnplc.com>Corporate>Governance*

DESCRIPTION OF THE SHARE CAPITAL AND THE SHARES

1.10. Capital Structure

1.10.1 Issued Capital

As of 11 January 2024, the Company's issued share capital consists of 4,785,474 New Ordinary Shares of £0.0001, 23,265,104 deferred shares of £0.99 (the “**Existing £0.99 Deferred Shares**”), 435,935,792 deferred Shares of £0.0099 (the “**Existing £0.0099 Deferred Shares**”) (the Existing £0.99 Deferred Shares and the Existing £0.0099 Deferred Shares together being the “**Existing Deferred Shares**”) and 4,785,474 New Deferred Shares of £0.0999 in issue.

Ordinary Share:

The Shares are fully paid and rank pari passu with each other. The shares have attached to them full voting, dividend and capital distribution (including on winding up) rights; they do not confer any rights of redemption.

Deferred Shares:

The shares carry no right to receive notice of, or to attend, speak or vote at any general meeting: They confer no right to participate in dividends or other distributions.

1.10.2 Authorized Capital / Authority to allot shares / Pre-emption rights

English law, provides for an authorization to allot shares and to disapply pre-emption rights as set out below.

Pursuant to section 551 Companies Act 2006, the directors of a company be generally and unconditionally authorised under section 551 of the Companies Act 2006 to

exercise all the powers of the Company to allot shares in the Company and to grant rights to subscribe for, or to convert any security into, shares in the Company ("**Rights**") up to an aggregate nominal amount of £3,500,000.

The directors of the Company shall have the power to allot equity securities (within the meaning of section 560 of the Companies Act 2006) for cash under the authority as if section 561 of the Companies Act 2006 did not apply to the allotment;

This power applies in relation to a sale of treasury shares which constitutes an allotment of equity securities by virtue of section 560(3) of the Companies Act 2006.

The Company be, and it is hereby, generally and unconditionally authorised for the purpose of sections 693 and 701 of the Companies Act 2006 to make one or more market purchases (within the meaning of section 693(4) of the Companies Act 2006) of ordinary shares of £0.01 each in the capital of the Company upon such terms and in such manner as the directors of the Company shall determine, provided that:

1.10.3 Conditional Capital

As of the date of this document the Company has no conditional share capital. For the authorizations of the directors to allot additional shares pursuant to the laws of England and Wales, see section 1.10.2 above.

1.11. Clearing Codes

ISIN is GB00BM9PTW47 and the company's primary listing is on Euronext Growth Market, Ticker Symbol is ALRPD.

1.12. Type of Shares, Certification and Form of Shares

The Company has in issue 4,785,474 ordinary registered Shares with a nominal value of GBP 0.0001.

The Shares have been validly created under the Companies Act 2006.

The Shares are partially represented by individual certificates and partially as uncertificated securities. Shares in the form of uncertificated securities are held with CREST and Clearstream. Clearing and settlement with respect to such Shares traded over Euronext Growth Paris occurs typically through Euroclear. CREST is a paperless settlement procedure operated by Euroclear UK & Ireland Limited enabling securities to be evidenced otherwise than by a certificate and transferred otherwise than by a written instrument. CREST is a voluntary system, therefore shareholders of uncertificated Shares have the right under English law to receive and retain physical share certificates from the Company. However, Shares in certificated form cannot be held or traded in CREST. Shareholders who wish to hold their Shares in certificated form would need to withdraw their Shares from CREST in order to clear and settle such Shares through Euroclear, respectively.

A corporate shareholder can hold Shares in CREST directly, provided that it has become a direct CREST member and has the hardware and software to connect directly with CREST, or via a sponsor, a CREST member who offers such services to other companies. An individual shareholder can open an account in his or her name with a stockbroker who is a CREST member, in which case the individual's name remains on

the company's register and the individual is the legal and beneficial owner of the securities. Accordingly, the individual receives dividends, corporate action notifications and other documentation directly from the company's registrar and will be able to attend and vote at the meetings of shareholders.

More commonly, the individual transfers his or her securities into a nominee account with a stockbroker or custodian bank acting as nominee for the beneficial owners of the shares. Such a stockbroker or custodian bank is either a direct member of CREST or relies on services of a CREST member. The nominee holds the Shares on behalf of the individual and is the legal owner of the shares, and the shares are registered in the name of the nominee in the company's register. The individual retains beneficial ownership and will receive dividends, corporate action notifications and other documentation via the nominee. Underlying beneficial owners of Shares who wish to obtain a confirmation of their shareholding need to contact their broker or custodian bank.

1.13. Dividends and Dividend Policy

1.13.1 Dividend Policy and Restrictions

The Company has no dividend policy at the date of this document. The Board will determine – pursuant to the Company's Articles - what, if any, dividends are to be distributed to shareholders from time to time taking into account the profitability and strategic direction of the Company, and such other matters as the Board may consider relevant. The Board has no restrictions on its ability to determine a dividend policy and there are no restrictions in place relating to the payment of dividends.

The Company has not paid any dividends since its incorporation on 11 January 2012. The Company will maintain a paying agent in Paris for the distribution of any dividends for as long as its Shares are listed on Euronext Growth Paris. The Company's paying agent in Paris is currently Financière d'Uzès.

1.14. Voting Rights

Subject to limitations of electronic trading platforms and custodian arrangements, each shareholder of the Company who holds fully paid Shares has the following rights as determined by the Articles of Association and the laws of England and Wales:

- (a) Right to attend and speak at general meetings;
- (b) Right to vote at a general meeting;
- (c) Right to receive dividends.

The rights attached to the Shares only apply to the shareholders listed in the company register. For Shares in the form of uncertificated securities, the nominee will be registered in the company register and not the underlying beneficial owner. Therefore, only the nominee has the right to vote, attend meetings and receive dividends. The rights of the beneficial owners are thus derivative in nature. In practice, the underlying beneficial owners of Shares would normally be contacted by their broker or custodian bank with regard to matters communicated by the Company to its shareholders, such as with respect to shareholder meetings, dividends, etc.

The Company has only issued ordinary shares, and as such there are no preferences or restrictions that distinguish the shares in the company.

According to section 41 of the Company's Articles no voting rights attached to a share may be exercised at any general meeting unless all amounts payable to the Company in respect of that share have been paid. There are no additional voting restrictions applicable to the Shares under the laws of England and Wales.

Shareholders are entitled to appoint a proxy to exercise all or any of their rights to attend and to speak and vote on their behalf at the general meeting. A shareholder may appoint more than one proxy in relation to the general meeting provided that each proxy is appointed to exercise the rights attached to a different share or shares held by that shareholder. A proxy does not need to be a shareholder of the Company.

Subject to some specific cases where notice periods may vary including provisions of the Companies Act 2006 which require "special notice", the Directors may call a general meeting to obtain a vote of the members in the following circumstances with the requisite amount of notice:

- (a) for an annual general meeting at least 21 clear days' notice;
- (b) for any other general meeting other than an adjourned meeting, the directors must give shareholders at least 14 clear days' notice.

In the case where there are less than two directors, or one or more of the directors are unable or unwilling to call a general meeting, two shareholders may call such a meeting for the purpose of appointing one or more directors.

Ordinary Resolutions require a simple voting majority to be passed and Special Resolutions a voting majority of 75%, in each case with respect to votes cast at a shareholder's meeting.

1.15. Restriction of Transfer of Shares and Lock-up

As per the date of this document, there are no transfer restrictions or lock-up periods in the Company's Articles of Association or under the laws of England and Wales applicable with regard to the Shares (unless voluntarily by shareholders).

Special Provisions

As per the date of this document, there are no special provisions pursuant to the Company's Articles that differ from the laws of England and Wales in respect of changes to capital and the rights attached to the individual types of shares, other than as set out above.

2. TAXATION

2.1. Taxation in the United Kingdom

The following summary includes a description of the current tax position of Shareholders who are resident or ordinarily resident in the United Kingdom for tax purposes and holding ordinary Shares beneficially as investments. The statements below are intended only as a general guide and do not constitute advice to any shareholder on his personal tax position and may not apply to certain classes of investor who may be subject to special rules (such as dealers in securities, insurance companies, charities, collective investment schemes or pension providers). The comments are based on current legislation and H.M. Revenue & Customs, the department responsible for the collection of taxes in the United Kingdom, practice at the date of this document. Any investor who is in doubt as to their tax position or who is subject to taxation in a jurisdiction other than the United Kingdom, should consult his or her own professional advisers immediately. Shareholders should note that the levels and bases of, and relief from, taxation may change and that changes may affect benefits of investment in the Company. This summary is not exhaustive and does not generally consider tax relief or exemptions.

2.1.1 Taxation of Dividends

The Company will not be required to withhold tax at source when paying a dividend to UK tax resident individuals or companies. A United Kingdom resident individual shareholder will not generally pay tax on the first GBP 5,000 of dividends that they receive in a tax year. Above this allowance the tax a United Kingdom resident individual shareholder will pay depends on which Income Tax band they are in. The current dividend tax rates for the year end 5 April 2018 are as follows:

- Basic Rate: 7.5%
- Higher Rate: 32.5%
- Additional rate: 38.1%

Subject to certain exceptions, a Shareholder which is a company resident for tax purposes in the United Kingdom and which receives a dividend paid by another company resident for tax purposes in the United Kingdom will not generally have to pay corporation tax in respect of it.

Persons who are not resident in the United Kingdom should consult their own tax advisers concerning their tax liabilities on dividends received from the Company.

2.1.2 Taxation of Capital Gains

If a Shareholder disposes of any or all of his ordinary Shares in the Company he may incur a liability to tax on chargeable gains depending upon the Shareholder's particular circumstances and subject to any available exemptions and reliefs. Companies are entitled to indexation allowance which may also reduce the chargeable gain.

2.1.3 Other Taxes

The transfer of shares in the secondary market is generally subject to UK Stamp Duty Reserve Tax (SDRT). A purchase on Euronext Growth Paris of Shares in the form of uncertificated securities that are held with CREST and Clearstream and that are cleared and settled through Euroclear, currently triggers SDRT of 0.5 percent. This stamp tax is charged fully to the buyer of the Shares, and the buyer is liable for the payment. The buyer's bank normally assumes the responsibility for the required registration with the

HM Revenue and Customs (HMRC), the tax, payments and customs authority of the United Kingdom and the correct deduction and reporting of the tax on behalf of its customer. Certain transfers and purchases are normally exempt from SDRT, such as qualifying transfers between recognized intermediaries and clearing houses or purchases by UK registered charities. Transfers of certificated Shares are subject to a stamp duty of 0.5 per cent, when the transaction value exceeds GBP 1,000.

2.2. Paying Agent

As long as the Shares are listed on the Euronext Growth Paris, the Company will maintain a principal paying agent in Paris. The Company's paying agent in Paris is Financière d'Uzès.

2.3. Listing Sponsor

As long as the Shares are listed on the Euronext Growth Paris, the Company will maintain a Listing Sponsor in Paris. The Company's Listing Sponsor in Paris is Banque In Extenso Financement & Marché.

2.4. Liquidity Provider

As long as the Shares are listed on the Euronext Growth Paris, the Company will maintain a liquidity contact with an approved firm in Paris. The Company's Liquidity Provider in Paris is Tradition Securities and Futures (TSAF SA).

2.5. Information Policy

Copies of the Company's Articles of Association as well as the Company's annual reports for the past three years are available at the offices of Rapid Nutrition PLC at Suite A, 82 James Carter Road, Midenhall Suffolk IP28 7DE (telephone number: +44 20 3239 2561; e-mail: info@rnplc.com) during regular business hours.

2.6. Notices

According to the Company's Articles of Association and the statutory law of England and Wales, notices to Shareholders are validly made via registered mail to the nominee registered address in the United Kingdom.

Publications in connection with the listing of the Shares are made in compliance with the applicable Listing Rules of Euronext Growth Paris. Significant changes to the information contained in this document occurring until the first trading day of the New Shares at Euronext Growth Paris will be published via an official notice with Euronext Growth Paris. The Company publishes financial information and press releases in the electronic media and on its website at <http://www.rnplc.com/>.

3. GLOSSARY OF DEFINED TERMS

Act	means the Companies Act 1985 (as amended) and the Companies Act 2006 of the United Kingdom to the extent in force.
Articles	means the Company's articles of association as amended.
ASIC	Australian Securities and Investments Commission.
AUD	means the lawful currency of Australia.
Australian Corporations Act	means Corporations Act 2001 of the Commonwealth of Australia.
Board	means the Board of Directors of the Company.
Company	means Rapid Nutrition PLC.
CREST	means the settlement system and central securities depository for the UK operated by Euroclear UK & Ireland Limited.
DCF	means discounted cash flow.
Director	means a member of the Board of Directors of the Company.
EEA	means the European Economic Area.
EMEA	means Europe, the Middle East and Africa.
EUR	means the lawful currency of the Member States of the European Communities that have adopted the Euro as its lawful currency in accordance with legislation of the European Community relating to the Economic and Monetary Union.
Exempt Investors	means an investors who fall within one or more of the categories of investors under section 708 of the Australian Corporations Act to whom an offer may be made without disclosure under Part 6D.2 of the Australian Corporations Act and are "wholesale clients" for the purpose of section 761G of the Australian Corporations Act.
FDA	means US Food and Drug Administration.
FSMA	means Financial Services and Markets Act 2000 of the United Kingdom.
GMP	means Good Manufacturing Practice.
Group	means the Company and its wholly owned subsidiary Rapid Nutrition Pty Ltd, Australia.
Group Companies	means the companies of the Group.
IFRS	means International Financial Reporting Standards as adopted by the European Union.
Initial Price	means the initial trading price for the Shares.
Listing	means the listing the New Shares of the Company according to the International Reporting Standard of Euronext Growth Paris.
Listing Rules	means the Listing Rules of Euronext Growth Paris.
PLC	mean a public limited company incorporated under the laws of England and Wales.
Prospectus Directive	means Directive 2003/71/EC and amendments thereto, including the 2014 Amending Directive.
PSC Register	means register of people with significant control pursuant to the Companies Act 2006.

Rapid Nutrition Pty	means the Company's subsidiary Rapid Nutrition Pty Ltd, Australia.
Relevant Member State	means the Member States of the European Economic Area which have implemented the Prospectus Directive.
R&D	means research and development.
SDRT	means UK Stamp Duty Reserve Tax.
SFA	means the Securities and Futures Act of Singapore.
Shareholders	means the shareholders of the Company.
Shares	means the ordinary shares with a nominal value of GBP 0.01 per share of the Company.
USD	means the lawful currency of the United States of America.
VDS	Vitamin and dietary supplements.
1933 Act	means the U.S. Securities Act of 1933, as amended.
2014 Amending Directive	means Directive 2014/51/EU of 16 April 2014.